Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 6/20 | 0.52 |
| ▸ | SSTR2 | P30874 | 6/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.52 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.52 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.46 |
| ▸ | CDC25B | P30305 | 6/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16581478 | 1.00 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6553544 | 0.96 | SSTR1 (0.51) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6553536 | 0.96 | SSTR1 (0.51) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2290681 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL6265877 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8721432 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL8721436 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12380695 | 0.95 | SSTR1 (0.52) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2589256 | 0.94 | SSTR1 (0.51) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL12468632 | 0.94 | SSTR1 (0.51) | SSTR1SSTR2SSTR4SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735975-B1 | ERTUGLIFLOZIN FOR USE IN TREATING HEART FAILURE IN PATIENTS WITH DIABETES | MERCK SHARP & DOHME LLC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-2627691-B1 | DEGRADABLE POLYCARBONATES | TEXAS A&M UNIV (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3735975-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELATED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054598-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2020-02-20 | — | — | US | disclosed |
| US-20200038368-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELTED DISEASES USING SGLT-2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2019-12-10 | — | — | US | disclosed |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| EP-2334687-B9 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. | 2012-07-19 | — | — | US | disclosed |
| WO-2012051448-A1 | DEGRADABLE POLYCARBONATES | TEXAS A&M UNIVERSITY (US) | 2012-04-19 | — | — | WO | disclosed |
| EP-2334687-B1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8080580-B2 | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| WO-2011051864-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC | 2010-03-04 | — | — | US | disclosed |
| EP-0642799-B1 | Improved prodrugs for enzyme mediated activation | HOECHST AG (DE) | 2001-11-07 | — | — | EP | disclosed |
| US-5621002-A | HAVING A MODIFIED COMPETITIVE ENZYME ACTIVITY INHBITOR LINKED TO A SPACER-DRUG; ENZYME CLEAVAGE AT A LOWER CONCENTRATION, I.E. LOW MICHAELIS-MENTEN CONSTANT(KM) | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
| EP-0642799-A1 | Improved prodrugs for enzyme mediated activation | BEHRINGWERKE Aktiengesellschaft (DE) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | SSTR1 791/4885SSTR2 371/4885SSTR4 621/4885 |
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | SSTR1 852/4885SSTR2 355/4885SSTR4 759/4885 |
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | SSTR1 852/4885SSTR2 355/4885SSTR4 759/4885 |
| US-20200054598-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | SSTR1 852/4885SSTR2 355/4885SSTR4 759/4885 |
| US-20200038368-A1 | METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR EVENTS AND RELTED DISEASES USING SGLT-2 INHIBITORS | SLC5A1, SLC5A2, SLC2A1 | SSTR1 1145/4885SSTR2 976/4885SSTR4 887/4885 |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | SSTR1 852/4885SSTR2 355/4885SSTR4 759/4885 |
| US-20120184486-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | SSTR1 925/4885SSTR2 357/4885SSTR4 569/4885 |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | SSTR1 817/4885SSTR2 335/4885SSTR4 732/4885 |
| US-12036203-B2 | Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors | SLC5A1, SLC5A2, GLP1R | SSTR1 905/4885SSTR2 691/4885SSTR4 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.